综述:肝硬化与门静脉高压患者心房颤动的诊断、病理生理与管理
该综述通过广泛文献检索,从心脏病学与肝病学角度概述肝硬化患者心房颤动的诊断、病理生理与管理。肝硬化患者心房颤动患病率为6.6%至14.2%,肝移植术后新发心房颤动发生率为6.8%至10.2%。无严格禁忌时所有肝硬化合并心房颤动患者应抗凝,直接口服抗凝药优于维生素K拮抗剂。
要点
- 肝硬化患者心房颤动患病率为6.6%至14.2%,肝移植术后新发心房颤动发生率为6.8%至10.2%。
- 无严格禁忌时所有肝硬化合并心房颤动患者应抗凝,直接口服抗凝药优于维生素K拮抗剂。
- 高出血风险患者可优先选择有获批拮抗剂的直接口服抗凝药。
核心结论
- 肝硬化患者心房颤动发生率增加,心房颤动管理需仔细权衡治疗选择。
- 因所有重大随机临床试验均排除肝硬化患者,需专门研究肝硬化心房颤动的病理生理与管理。
研究设计与样本
- 综述:使用「心房颤动」与「肝硬化」进行广泛文献检索,并查阅指南文件与共识声明。
主要发现
- 肝硬化患者心房颤动患病率为6.6%至14.2%。
- 肝移植术后新发心房颤动发生率为6.8%至10.2%。
- 肝硬化患者心房颤动与移植前和移植后不良结局相关,包括与一般人群相比卒中风险增加。
关键数值与推荐
- 无严格禁忌时,所有肝硬化合并心房颤动患者应抗凝。
- 直接口服抗凝药优于维生素K拮抗剂。
- 高出血风险患者可优先选择有获批拮抗剂的直接口服抗凝药。
临床怎么用
- 无严格禁忌时,所有肝硬化合并心房颤动患者应抗凝。
- 直接口服抗凝药优于维生素K拮抗剂。
- 高出血风险患者可优先选择有获批拮抗剂的直接口服抗凝药。
局限性
- 所有重大随机临床试验均排除肝硬化患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atrial fibrillation (AF) is the most common arrhythmia and its management in cirrhosis can be challenging due to the altered hepatic metabolism of medications and increased risk of bleeding. AIMS: To provide a comprehensive overview of the diagnosis, pathophysiology and management of AF in patients with cirrhosis from both a cardiology and a hepatology perspective. METHODS: An extensive literature search was performed using the terms 'atrial fibrillation' and 'cirrhosis'. Guideline documents and consensus statements were explored. RESULTS: The prevalence of AF in patients with cirrhosis ranges between 6.6% and 14.2%, while the incidence of new-onset AF in the post-operative period after liver transplant ranged between 6.8% and 10.2%. AF in patients with cirrhosis is associated with adverse outcomes in both pre-transplant and post-transplant settings, including an increased risk of stroke when compared to the general population. We review the pathogenesis of AF in general and in cirrhosis. This review also provides guidance on the management of AF, including the use of anticoagulation and rate versus rhythm control. In the absence of strict contraindications, all patients with cirrhosis and AF should be anticoagulated. The use of DOACs is preferred over vitamin K antagonists. In patients with a high bleeding risk, a DOAC with an approved antidote may be preferred. CONCLUSIONS: Atrial fibrillation is increased in patients with cirrhosis. AF management requires careful consideration of treatment options. Since patients with cirrhosis were excluded from all major randomised clinical trials, dedicated research on the pathophysiology and management of AF in cirrhosis is needed.
引用
- Vandenberk B, Altieri MH, Liu H, et al. Review article: diagnosis, pathophysiology and management of atrial fibrillation in cirrhosis and portal hypertension. Aliment Pharmacol Ther. 2022. PMID: 36571829. doi:10.1111/apt.17368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。